Ethris reports positive phase 1 results for ETH47 mRNA asthma treatment
Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy...
Lantheus acquires radiopharma CDMO Evergreen
The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which...
Novo Nordisk reports 22% weight loss with amycretin
Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug,...
Manas AI launches with $24.6 million seed round
The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic...
Applying data to real-world challenges
Head of solution value at One2Treat, Émilie Barré shares her journey to date with Outsourcing-Pharma. Could you give us an overview of your work? I...
The largest pharma acquisitions of 2024
Compared to the previous years, 2024 has been a relatively slow year for mergers and acquisitions in the pharmaceutical space. The largest acquisition of 2024...
Arctic therapeutics secures funding for groundbreaking dementia and acne treatments
Arctic Therapeutics announced this week that it has raised €26.5 million, a sum bankrolled by investors including the European Innovation Council (EIC) Fund, the Icelandic...
Trial shows high-dose Wegovy can increase weight loss effects
Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for....
BioCina and NovaCina join forces in merger
Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and...
AI proving critical in clinical trial design
We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025 Achievements and milestones...
Spotlight on patient centricity in clinical trials
We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical...
Medable Showcases AI-Powered Innovations at SCOPE 2025
Stakeholders across the clinical trials and digital health industry will be gathering next month in Orlando at the Summit for Clinical OPS Executives (SCOPE) 2025....
Tech key to accelerating clinical trial outcomes
Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market...
WCG’s outlook for SCOPE 2025
As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2...
Patient Perspectives and Multidimensional Assessments
The evolution of clinical trials is being driven by an increased focus on patient perspectives and innovative statistical methodologies. Regulatory agencies are pushing for trials...
Johnson & Johnson acquires Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has entered an acquisition agreement with drug developer Intra-Cellular Therapies priced at $14.6bn, positioning the deal as one of the largest seen...
Scope Summit 2025 award finalists announced
As the Cambridge Healthtech Institute (CHI) celebrates its 16th annual Clinical Ops Executives (SCOPE) Summit in Orlando, Florida, USA, next month, two awards, one for...
Anthem Biosciences plans IPO worth $397m
As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences is planning to raise 33.95 billion rupees...
Verdiva Bio’s launch is backed by financing of over $410m
The company’s launch is backed by an oversubscribed Series A round of $411m co-led by Forbion and General Atlantic. RA Capital Management, OrbiMed, Logos Capital,...
Denali’s ALS Drug DNL343 Misses Key Trial Endpoint
Denali Therapeutics has announced topline results from the phase 2/3 Healey ALS Platform Trial, which evaluated the effects of its drug candidate DNL343. The study...